智通财经APP获悉，据港交所1月26日披露，上海奥科达医药科技股份有限公司(简称：奥科达医药)向港交所主板递交上市申请书，招商证券国际、建银国际为其联席保荐人。招股书显示，奥科达医药拥有自主研发的创新的药物递送平台，搭建了覆盖研发、生产及销售和营销的一体化内部体系，并组建了丰富的全球产品管线。公司采用505(b)(2)注册路径，聚焦特定治疗领域，借助自主构建的全体系研发、生产及商业化能力，实现运营协同效应。
智通财经APP获悉，据港交所1月26日披露，上海奥科达医药科技股份有限公司(简称：奥科达医药)向港交所主板递交上市申请书，招商证券国际、建银国际为其联席保荐人。招股书显示，奥科达医药拥有自主研发的创新的药物递送平台，搭建了覆盖研发、生产及销售和营销的一体化内部体系，并组建了丰富的全球产品管线。公司采用505(b)(2)注册路径，聚焦特定治疗领域，借助自主构建的全体系研发、生产及商业化能力，实现运营协同效应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.